|Dr. Vipin K. Garg||Pres, CEO & Director||566.63k||N/A||1958|
|Mr. William Michael Brown||CFO & Principal Accounting Officer||443.16k||N/A||1982|
|Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF||Chief Medical Officer||371.29k||N/A||1953|
|Mr. Bertrand Georges Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Dr. M. Scot Roberts||Chief Scientific Officer||N/A||N/A||1959|
|Mr. JosÃ© Ochoa||Chief Bus. Officer||N/A||N/A||N/A|
Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.